Blog
RSS FeedPosted by Michael Wonder on 02 Apr 2025
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A (final guidance)
2 April 2025 - NICE has published final evidence-based recommendations on the use of efanesoctocog alfa (Altuvoct) for the treatment ...
Posted by Michael Wonder on 17 May 2024
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A
17 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Jun 2020
Successful Eloctaq bid should widen access to the drug in the UK
29 June 2020 - The NHS and Sobi UK have come to an agreement that will give people living with ...
Posted by Michael Wonder on 21 Apr 2020
Andexanet alfa for reversing anticoagulation
21 April 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using andexanet alfa ...
Posted by Michael Wonder on 27 Sep 2018
Draft NICE decision rejects Respreeza for incurable, genetic disorder
27 September 2018 - NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in ...